| Prev Close | 42.73 |
| Open | 42.59 |
| Day Low/High | 42.03 / 42.79 |
| 52 Wk Low/High | 33.20 / 46.47 |
| Volume | 28.27M |
| Avg Volume | 23.70M |
Pfizer Inc. (PFE)
42.08
0.65
1.50
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 5.78B |
| Market Cap | 244.92B |
| EPS | 3.60 |
| P/E Ratio | 10.73 |
| Div & Yield | 1.44 (3.17%) |
Latest News
This Market May Just Be in an Uptrend: Market Recon
This is the kind of reversal that happens in a bull market.
Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
This 2019 Market Optimism Is Misplaced: Market Recon
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Pfizer Shares Jump on Monday After Company Signals Higher Price Push
Pfizer pushes higher on price increases.
Bulls Stampeded by Bears as FAANG Stocks Get Trampled
A retest of the October lows seems almost too obvious but it is hard to dispute the possibility that it may occur.
Tech Selloff Could Work in Favor of Pharmaceutical Stocks
Pharma could be the best parking spot for your money if the market keeps trending downward.
Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing
Shares of the New York City-based pharmaceutical giant are rising on Monday.
Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility
Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.
Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Pfizer Could Rally in the Weeks Ahead as Investors Look Beyond Today's Headline
Let's check our indicators.
Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases
Pfizer may have poked the bear.
Eli Lilly's Conservative Pricing Offers Protection From Political Pressure
Eli Lilly's self-policing on drug pricing protects it from the most prominent political pushbacks.
4 Scenarios That Will Impact the Market: Market Recon
And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.
Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken
Once the safest stocks in the book, the big-cap drug companies are now toxic.
Jim Cramer: Here's What I Saw That Justified Today's Rally
Some groups that have been in horrendous bear market mode finally caught a bid.
Staying Long Apple Into Tuesday's Product Launch: Market Recon
My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.
Here Are 9 Takeaways From Last Night's Meltdown: Market Recon
It becomes difficult for me to tell you where to run in these markets...
Tesla Produced A Record Number of Vehicles in Q3, Report Says: LIVE MARKETS BLOG
Tesla produced 80,000 vehicles in the quarter, according to electrek.
Door Hits 2 CEOs in the Behind
We are about a 20 minutes from the open of a new trading week. Futures are up on news of a trade agreement between Canada and the United States that will lessen overall trade tensions and allow the country to focus on China. Tesla up strongly in pre...
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
Closing Bell: LIVE MARKETS BLOG
Markets were higher Tuesday after starting Tuesday's session off in the green.
Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown
The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.
Pfizer Reached Our Price Target, So We Could Pause Here Before Heading Higher
Traders should raise sell stops to just above $40 from below $35.50
